GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » PE Ratio

Mega Genomics (HKSE:06667) PE Ratio : 65.23 (As of Jun. 05, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-06-05), Mega Genomics's share price is HK$9.98. Mega Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.15. Therefore, Mega Genomics's PE Ratio for today is 65.23.

During the past 5 years, Mega Genomics's highest PE Ratio was 78.95. The lowest was 14.26. And the median was 23.42.

Mega Genomics's EPS (Diluted) for the six months ended in Dec. 2023 was HK$-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.15.

As of today (2024-06-05), Mega Genomics's share price is HK$9.98. Mega Genomics's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.08. Therefore, Mega Genomics's PE Ratio without NRI ratio for today is 121.71.

During the past 5 years, Mega Genomics's highest PE Ratio without NRI was 4133.33. The lowest was 13.77. And the median was 2601.67.

Mega Genomics's EPS without NRI for the six months ended in Dec. 2023 was HK$-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.08.

During the past 12 months, Mega Genomics's average EPS without NRI Growth Rate was 2600.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -40.70% per year.

During the past 5 years, Mega Genomics's highest 3-Year average EPS without NRI Growth Rate was -40.70% per year. The lowest was -73.50% per year. And the median was -57.10% per year.

Mega Genomics's EPS (Basic) for the six months ended in Dec. 2023 was HK$-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.15.

Back to Basics: PE Ratio


Mega Genomics PE Ratio Historical Data

The historical data trend for Mega Genomics's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics PE Ratio Chart

Mega Genomics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
N/A N/A N/A At Loss 67.32

Mega Genomics Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
PE Ratio Get a 7-Day Free Trial N/A At Loss At Loss At Loss 67.32

Competitive Comparison of Mega Genomics's PE Ratio

For the Diagnostics & Research subindustry, Mega Genomics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mega Genomics's PE Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Mega Genomics's PE Ratio falls into.



Mega Genomics PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Mega Genomics's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=9.98/0.153
=65.23

Mega Genomics's Share Price of today is HK$9.98.
For company reported semi-annually, Mega Genomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.15.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Mega Genomics  (HKSE:06667) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Mega Genomics PE Ratio Related Terms

Thank you for viewing the detailed overview of Mega Genomics's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Mega Genomics (HKSE:06667) Business Description

Traded in Other Exchanges
N/A
Address
North Garden Road, 401 Health Work, Haidian District, Beijing, CHN
Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.
Executives
Guo Meiling 2101 Beneficial owner
Lin Lin 2101 Beneficial owner
Yu Rong 2501 Other
Infinite Galaxy Health Limited 2101 Beneficial owner
Mei Nian Investment Limited 2101 Beneficial owner
Kastle Limited 2501 Other
Mega Marvelous Limited 2501 Other
Yurong Technology Limited 2101 Beneficial owner
Niu Zhencai 2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si 2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines